Buy Day today: Good (67) Broad market participation · no major macro event

Crispr Therapeutics AG (CRSP)

Healthcare Biotechnology

49.60 $

+3.3% vs. previous close

Closing price · As of: 3. Aug 2026

Crispr Therapeutics AG (CRSP) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 2,265 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow

Annual Quarterly

All figures in millions of USD.

Balance Sheet CRSP
Tick rows to compare them in a chart (up to 4)	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	1.5	159	345	271	489	1,067	1,828	2,752	2,243	2,230	2,242	2,265
Current Assets	1.0	157	320	248	466	988	1,717	2,418	1,853	1,908	1,937	1,986
Cash	0.9	156	316	240	457	944	1,169	923	212	389	298	355
Cash & Short-Term Investments	0.9	156	316	240	457	944	1,690	2,379	1,815	1,694	1,904	1,976
Receivables	3.0	0.3	3.2	2.6	0.1	0.1	11	0.3	11	200	25	0.0
Inventory	–	0.0	0.0	0.0	0.0	0.0	–	–	-11	–	–	–
Property, Plant & Equipment	–	1.3	21	19	19	73	42	138	164	–	–	–
Goodwill	–	–	0.0	0.0	–	–	–	–	–	–	–	–
Intangible Assets	0.5	0.5	0.4	0.3	0.3	0.2	0.2	0.1	0.1	0.0	–	–
Total Liabilities	8.5	189	112	84	97	127	164	352	368	347	310	343
Current Liabilities	2.1	10	22	15	28	57	94	120	121	109	88	149
Short-Term Debt	38	38	60	44	35	8.5	11	12	16	16	17	19
Accounts Payable	0.2	1.6	4.6	1.6	5.1	5.9	9.1	15	27	38	15	11
Long-Term Debt	38	38	0.0	0.0	–	–	–	–	–	–	–	–
Shareholders' Equity	-7.1	-29	233	188	392	939	1,664	2,399	1,875	1,883	1,932	1,922
Retained Earnings	-8.4	-34	-57	-125	-292	-225	-574	-196	-846	-1,000	-1,366	-1,948
Shares Outstanding	29	29	12	40	48	57	66	80	78	79	84	90

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cookie settings